Morphogen receptor genes and metamorphogenes: Skeleton keys to metamorphosis

Annals of the New York Academy of Sciences

Volumn 1116, Issue , 2007, Pages 113-133

  Kaplan, Frederick S ^a,c   Groppe, Jay ^b   Pignolo, Robert J ^a   Shore, Eileen M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ACVR1; BMP; BMP receptor; BMP signaling pathways; Bone morphogenetic protein; Fibrodysplasia ossificans progressiva; Heterotopic ossification; Metamorphogene; Metamorphosis; Morphogen; Morphogen receptor

Indexed keywords

MORPHOGEN; MORPHOGEN RECEPTOR; PROCOLLAGEN C PROTEINASE; UNCLASSIFIED DRUG;

APONEUROSIS; AUTOSOMAL DOMINANT DISORDER; BONE DEVELOPMENT; BONE REGENERATION; BONE REMODELING; CARCINOGENESIS; CELL FATE; CONFERENCE PAPER; EPIGENETICS; FASCIA; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; FIBROUS DYSPLASIA; GENETIC CODE; HETEROTOPIC OSSIFICATION; HUMAN; HUMAN GENOME; IMMUNE SYSTEM; LIGAMENT; METAMORPHOSIS; MISSENSE MUTATION; MORPHOGENESIS; NONHUMAN; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE; STEM CELL; TENDON; TISSUE ENGINEERING;

MAMMALIA; VERTEBRATA;

EID: 37249082497     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1402.039     Document Type: Conference Paper

References (89)

1. MANDELBAUM, A. 1993. The Metamorphoses of Ovid. Harcourt, New York.
2. KAFKA, F. 1948. The Metamorphosis. Schocken Books. New York.
3. GILBERT, S. 2000. Developmental Biology. Sinauer Associates Sunderland, MA.
4. KAPLAN, F.S. et al. 1998. Editorial comment. Clin. Orthop. Rel. Res. 346: 2-4.
5. CONNOR, J.M. & D.A. EVANS. 1982. Fibrodysplasia ossificans progressiva: the clinical features and natural history of 34 patients. J. Bone Joint Surg. Br. 64: 76-83.
6. COHEN, R.B. et al. 1993. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva (FOP) J. Bone Joint Surg. Am. 75: 215-219.
7. KAPLAN, F.S. et al. 2005. The phenotype of fibrodysplasia ossificans progressiva (FOP). Clin. Rev. Bone Miner. Metab. 3: 183-188.
8. GLASER, D.L. & F.S. KAPLAN. 2005. Treatment considerations for the management of fibrodysplasia ossificans progressiva. Clin. Rev. Bone Miner. Metab. 3: 243-250.
9. KAPLAN, F.S. et al. 2005. Introduction. Clin. Rev. Bone Miner. Metab. 3: 175-177.
10. KAPLAN, F.S. & D.L. GLASER. 2005. Thoracic insufficiency syndrome in patients with fibrodysplasia ossificans progressiva. Clin. Rev. Bone Miner. Metab. 3: 213-216.
11. ROSENSTIRN, J.A. 1918. A contribution to the study of myositis ossificans progressiva. Ann. Surg. 68: 485-520; 591-637.
12. KAPLAN, F.S. 2006. The key to the closet is the key to the kingdom. Orphan Disease Update 24: 1-9.
13. MAEDER, T. 1998. A few hundred people turned to bone. Atlantic Monthly 281: 81-89.
14. PIGNOLO, R.J. et al. 2005. The fibrodysplasia ossificans progressiva lesion. Clin. Rev. Bone Miner. Metab. 3: 195-200.
15. URIST, M.R. 1965. Bone formation by autoinduction. Science 150: 893-899.
16. WOZNEY, J.M. et al. 1988. Novel regulators of bone formation: molecular clones and activities. Science 242: 1528-1534.
17. KAPLAN, F.S. et al. 1993. The histopathology of fibrodysplasia ossificans progressiva: an endochondral process. J. Bone Joint Surg. Am. 75: 220-230.
18. GANNON, F.H. et al. 1998. Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clin. Orthop. Rel. Res. 346: 19-25.
19. GANNON, F.H. et al. 2001. Mast cell involvement in fibrodysplasia ossificans progressiva. Hum. Pathol. 32: 842-848.
20. GLASER, D.L. et al. 2003. In vivo somatic call gene transfer of an engineered noggin mutein prevents BMP4-induced heterotopic ossification. J. Bone Joint Surg. Am. 85: 2332-2342.
21. KAN, L. et al. 2004. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am. J. Pathol. 165: 1107-1115.
22. KATAGIRI, T. et al. 1994. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 127: 1755-1766.
23. AKIYAMA, S. et al. 1997. Constitutively active BMP type I receptors transduce BMP2 signals without the ligand in C2C12 myoblasts. Exp. Cell Res. 235: 362-369.
24. STOICK-COOPER, C.L. 2007. Advances in signaling in vertebrate regeneration as a prelude to regenerative medicine. Genes Dev. 21: 1292-1315.
25. FERGUSON, C. et al. 1999. Does adult fracture repair recapitulate embryonic skeletal formation? Mech. Dev. 87: 57-66.
26. ITO, M. et al. 2007. Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature 47: 316-320.
27. CHUONG, C-M. 2007. Regenerative biology: newhair from healing wounds. Nature 447: 265-266.
28. ZHANG, X. et al. 2002. Cyclooxyenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J. Clin. Invest. 109: 1405-1415.
29. KAPLAN, F.S. et al. 2007. Hematopoietic stem-cell contribution to ectopic skeletogenesis. J. Bone Joint Surg. Am. 89: 347-357.
30. TSUJI, K. et al. 2006. BMP2 activity, although dispensable for bone formation is required for the initiation of fracture healing. Nat. Genet. 38: 1424-1429.
31. LANDER, A.D. 2007. Morpheus unbound: reimagining the morphogen gradient. Cell 128: 245-256.
32. CUNNINGHAM, N.S. et al. 1992. Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta1 mRNA expression. Proc. Natl. Acad. Sci. USA 89: 11740-11744.
33. MAXWELL, W.A. et al. 1978. Elevated prostaglandin production in cultured cells from a patient with fibrodysplasia ossificans progressiva. Prostaglandins 15: 123-129.
34. KAPLAN, F.S. et al. 2005. Immunological features of fibrodysplasia ossificans progressiva (FOP) and the dysregulated BMP4 pathway. Clin. Rev. Bone Miner. Metab. 3: 189-193.
35. KITTERMAN, J.A. et al. 2005. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva (FOP). Pediatrics 116: 654-661.
36. MASSAGUÉ, J. 2000. How cells read TGF-β signals. Nat. Rev. Mol. Cell Biol. 1: 169-178.
37. HOFFMAN, A. & G. GROSS. 2001. BMP signaling pathways in cartilage and bone formation. Critical Rev. Eukaryotic Gene Exp. 11: 23-45.
38. TEN DIJKE, P. et al. 2003. Controlling cell fate by bone morphogenetic protein receptors. Mol. Cell Endocrinol. 211: 105-113.
39. KLOEN, P. et al. 2003. BMP signaling components are expressed in human fracture callus. Bone 33: 362-371.
40. CANALIS, E. et al. 2003. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocrine Rev. 24: 218-235.
41. SHI, Y. & J. MASSAGUÉ. 2003. Mechanisms of TFG-β signaling from cell membrane to the nucleus. Cell 113: 685-700.
42. MASSAGUÉ, J. et al. 2005. Smad transcription factors. Genes Dev. 19: 2783-2810.
43. HARTUNG, A. et al. 2006. Yin and yang in BMP signaling: impact on the pathology of disease and potential for regeneration. Signal Transduction 6: 314-328.
44. KAPLAN, F.S. et al. 1990. Fibrodysplasia ossificans progressiva (FOP): a clue from the fly? Calcif. Tiss. Int. 47: 117-125.
45. SHAFRITZ, A.B. et al. 1996. Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N. Engl. J. Med. 335: 555-561.
46. GANNON, F.H. et al. 1997. Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva (FOP). Hum. Pathol. 28: 339-343.
47. AHN, J. et al. 2003. Paresis of a bone morphogenetic protein - antagonist response in a genetic disorder of heterotopic skeletogenesis. J. Bone Joint Surg. Am. 85: 667-674.
48. SERRANO DE LA PEÑA, L. et al. 2005. Fibrodysplasia ossificans progressiva (FOP): a disorder of ectopic osteogenesis misregulates cells surface expression and trafficking of BMPRIA. J. Bone Miner. Res. 20: 1168-1176.
49. FIORI, J.L. et al. 2006. Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva. J. Bone Miner. Res. 21: 902-909.
50. KAPLAN, F.S. et al. 2006. Dysregulation of the BMP4 signaling pathway in fibrodysplasia ossificans progressiva. Ann. N.Y. Acad. Sci. 1068: 54-65.
51. BILLINGS, P.C. et al. 2008. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva. J. Bone Miner. Res. Submitted.
52. SHORE, E.M. et al. 2006. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet. 38: 525-527.
53. ZHANG, D. et al. 2003. Alk2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. J. Bone Miner. Res. 18: 1593-1604.
54. HARRADINE, K.A. & R.J. AKHURST. 2006. Mutations of TFG-β signaling molecules in human disease. Annals Med. 38: 403-414.
55. GROPPE, J.C. et al. 2007. Functional modeling of the ACVR1 (R206H) mutation in FOP. Clin. Orthop. Rel. Res. In press.
56. WANG, T. et al. 1996. The immunophilin FKBP12 functions as a common inhibitor of the TFG-β family type I receptors. Cell 86: 435-444.
57. CHEN, Y.-G. et al. 1997. Mechanism of TGF-β receptor inhibition by FKBP12. EMBO J. 16: 3866-3876.
58. HUSE, M. et al. 1999. Crystal structure of the cytoplasmic domain of the type I TGF- receptor complex with FKBP12. Cell 96: 425-436.
59. HUSE, M. et al. 2001. The TGF-β receptor activation process: an inhibitor-tosubstrate binding switch. Mol. Cell 8: 671-682.
60. EBISAWA, T. et al. 2001. Smurf1 interacts with transforming growth factor-β type 1 receptor through Smad 7 and induces receptor degradation. J. Biol. Chem. 276: 12477-12480.
61. YAMAGUCHI, T. et al. 2006. FKBP12 functions as an adaptor of the Smad7-Smurf1 complex on activin type I receptor. J. Mol. Endocrinol. 36: 569-579.
62. BRUNET, L.J. et al. 1998. Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science 280: 1455-1457.
63. GROPPE, J. et al. 2002. Structural basis of BMP signaling inhibition by the cystine knot protein noggin. Nature 420: 636-642.
64. KNUDSON, A.G. 1996. Hereditary cancer: two hits revisited. J. Cancer Res. Clin. Oncol. 122: 135-140.
65. KNUDSON, A.G. 2001. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1: 157-162.
66. JONES, P.A. & S.B. BAYLIN. 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Cancer 3: 414-428.
67. FUTREAL, P.A. et al. 2004. A census of human cancer genes. Nat. Rev. Cancer 4: 177-183.
68. VOGELSTEIN, B. & K.W. KINZLER. 2004. Cancer genes and the pathways they control. Nat. Med. 10: 789-799.
69. GONG, Y. et al. 1999. Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis. Nat. Genet. 21: 302-304.
70. KAPLAN, F.S. et al. 2005. Animal models of fibrodysplasia ossificans progressiva. Clin. Rev. Bone Miner. Metab. 3: 229-234.
71. RAUCH, C. et al. 2002. C2C12 myoblast/osteoblast transdifferentiation steps enhanced by epigenetic inhibition of BMP2 endocytosis. Am. J. Physiol. Cell Physiol. 283: 235-243.
72. FEINBERG, A.P. 2007. Phenotypic plasticity and the epigenetics of human disease. Nature 447: 433-440.
73. GOSDEN, R.G. & A.P. FEINBERG. 2007. Genetics and epigenetics - nature's penand-pencil set. N. Engl. J. Med. 356: 731-733.
74. REIK, W. 2007. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447: 425-432.
75. OLMSTED-DAVIS, E. et al. 2007. Hypoxic adipocytes pattern early heterotopic bone formation. Am. J. Pathol. 170: 620-632.
76. HAKIM, M. et al. 2005. Dexamethasone and recovery of contractile tension after a muscle injury. Clin. Orthop. Rel. Res. 439: 235-242.
77. JÄRVINEN, T.A.H. et al. 2005. Muscle injuries: biology and treatment. Am. J. Sports Med. 33: 745-764.
78. WYNN, T.A. 2007. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 117: 524-529.
79. VANDEN BOSSCHE, L.C. et al. 2007. Free radical scavengers are more effective than indomethacin in the prevention of experimentally induced heterotopic ossification. J. Orthop. Res. 25: 267-272.
80. SCHIPANI, E. et al. 2001. Hypoxia in cartilage: HIF-1 alpha is essential for chondrocyte growth arrest and survival. Genes Dev. 15: 2865-2876.
81. PFANDER, D. et al. 2003. HIF-1-alpha controls extracellular matrix synthesis by epiphyseal chondrocytes. J. Cell Sci. 116: 1819-1826.
82. PROVOT, S. et al. 2007. Hif-1-alpha regulates differentiation of limb bud mesenchyme and joint development. J. Cell Biol. 177: 451-464.
83. KAPLAN, F.S. et al. 2007. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton. Exp. Opin. Biol. Ther. 7: 705-712.
84. MOHLER, E.R., III et al. 2001. Bone formation and inflammation in cardiac valves. Circulation 103: 1522-1528.
85. KAPLAN, F.S. et al. 2004. Heterotopic ossification. J. Am. Acad. Orthop. Surg. 12: 116-125.
86. PIGNOLO, R.J. & K.L. FOLEY. 2005. Nonhereditary heterotopic ossification: implications for injury, arthropathy, and aging. Clin. Rev. Bone Miner. Metab. 3: 261-266.
87. WOLF, J.M. 2006. The genetics key to a rare disease and its impact on orthopedics. Orthopedics 29: 672.
88. POTTER, B.K. et al. 2006. Heterotopic ossification in the residual limbs of traumatic and combat-related amputees. J. Am. Acad. Orthop. Surg. 14: S191-S197.
89. WILLIS, R. 1989. The Works of William Harvey. University of Pennsylvania Press. Philadelphia, PA.